2015.5.28-30, 大阪.

17. Okumura A, Yamamoto T, Miyajima M, Shimojima K, Kondo S, Abe S, Ikeno M, Kurahashi H, Takasu M, Shimizu T. 3p interstitial deletion including *PRICKLE2* in identical twins with autistic features. 第57回日本小児神経学会学術集会. 2015.5.28-30, 大阪.

18. Kurahashi H, Okumura A, Igarashi A, Abe S, Takasu M, Kobayashi K, Ohmori I, Ouchida M, Hirose S, Ishii A, Takahashi S, Awaya T, Yamamoto T. An update of phenotype of infantile epilepsy with a *PRRT2* mutation. 第57回日本小児神経学会学術集会. 2015.5.28-30, 大阪.

19. 金子博之, 下島圭子, 山本俊至. 疾患iPS細胞による小児神経疾患の病態解析. JST-再生医療実現拠点ネットワークプログラム[疾患特異的iPS細胞を活用した難病研究]・JST-CREST[iPS細胞領域]合同シンポジウム「科学者たちによる難病への挑戦〜iPS細胞を用いた疾患研究〜」. 2015.2.23, 東京.

H. 知的所有権の取得状況

1. 特許取得
   なし
2. 実用新案登録
   なし
3. その他

小児慢性疾患名（日本語） 小児慢性疾患名（英　語）	WAGR 症候群 WAGR syndrome
カテゴリ	A
診断方法	I．主要臨床症状 1．無虹彩症：それに伴う弱視、緑内障など 2．知的障害 3．発達障害 4．腎尿路奇形：停留精巣、尿道下裂など 5．ウイルムス腫瘍 II．重要な検査所見 1．染色体検査：11p13 の微細欠失の確定（FISH、マイクロアレイなど） Definite：I の 1 に加え、2-5 のいずれかを認め、II の 1 を認めたもの。 Probable：I の 1 に加え、2-5 のいずれかを認めたもの。 Possible：I の 1 を認めたもの。
カテゴリAたる背景 科学的根拠	出生 8 万人に 1 人の発症率であり、希少なため、大規模な介入研究もなくエビデンスが限られている ＊患者家族会の HP 参照「日本ＷＡＧＲ症候群の会」 http://wagr.ho-plus.com/

厚生労働科学研究費補助金（難治性疾患政策研究事業）
分担研究報告書

マイクロアレイ染色体検査でみつかる染色体微細構造異常症候群の
診療ガイドラインの確立に関する研究

研究分担者　涌井 敬子　信州大学医学部遺伝医学・予防医学教室 講師

研究要旨：マイクロアレイ染色体検査により診断される、多発奇形・発達遅滞を主症状とする染色体微細構造異常症候群の診療ガイドラインの確立を目的として、代表的な疾患に関して、全国調査による国内患者の把握や、臨床診断基準、重症度判定基準の策定を実施する。これらの疾患の患者や家族に対する支援を通じて、稀少難病の医療や福祉の向上に貢献することをめざす.

A．研究目的
　マイクロアレイ染色体検査により診断される、多発奇形・発達遅滞を主症状とする染色体微細構造異常症候群の診療ガイドラインを確立する.

B．研究方法
　以下の染色体微細構造異常症候群：Feingold症候群(2p24.3欠失)，2q23.1欠失症候群(MBD5)，4p16欠失(Wolf-Hirschhorn症候群)，Cri-du-chat症候群(5pサブテロメア欠失)，Potocki-Lupski症候群(17p11.2重複)，Xp11.3-p11.4欠失(MAOA, MAOB, CASK)などについて，我が国における診療ガイドライン策定の参考資料とするため，国内外の臨床情報等をwebサイトにより検索，確認した.

（倫理面への配慮）
　本研究の実施に際しては，倫理指針等を遵守し，関係する多発奇形・発達遅滞を有する患者やその家族が不利益を被ることの無いよう，個人情報の保護に留意する。

C．研究結果
　GeneTests，OMIM，Orphanet，Unique，UR-DBMSなどに，我が国の診療ガイドライン策定の参考資料となる有用な情報が掲載されていることを確認した.

　GeneTests < https://www.genetests.org/>
　OMIM <http://omim.org>
　Orphanet <http://www.orpha.net/>
　Unique <http://www.rarechromo.org/>
　UR-DBMS <http://becomerich.lab.u-ryukyu.ac.jp/>

D．考察
　マイクロアレイ染色体検査が臨床検査として普及している諸外国においては，非常に稀な特定の染色体領域の微細構造異常症候群患者の情報も蓄積されてきていることがうかがえた.

E．結論
　引き続き情報収集に努め，各染色体微細構造異常症候群について我が国の診療ガイドラインを確立することにより，患者や家族に対する支援に繋げ、稀少難病の医療や福祉の向上に貢献することをめざす。

G．研究発表
 1．論文発表
　なし

 2．学会発表
　"pathogenic"と考えたCNVが症状を伴わない血縁者に検出されたら？（ポスター）涌井敬子、古庄知己、髙野亨子、山口智美、福嶋義光，第38回日本小児遺伝学会学術集会，2015.7.25，横浜

　Incidental findings（偶発的所見）を考える―細胞遺伝学的検査の視点から―（シンポジウム，口頭）涌井敬子，日本人類遺伝学会第60回大会，2015.10.16，東京

H．知的財産権の出願・登録状況
　　（予定を含む。）
 1．特許取得
　なし

 2．実用新案登録
　なし

 3.その他
　なし

III．研究成果の刊行に関する一覧表

別紙４

研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
黒澤健司	次世代シークエンサーを利用した遺伝性疾患のパネル解析	野村文夫	ますます臨床利用が進む遺伝子検査	メディカルドウ	東京	2015	28:38-42

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kurahashi H, Kato T, Miyazaki J, Nishizawa H, Nishio E, Furukawa H, Miyamura H, Ito M, Endo T, Ouchi Y, Inagaki H, Fujii T	Preimplantation genetic diagnosis/screening by comprehensive molecular testing.	Reprod Med Biol	15(1)	13-19	2015
Miyazaki J, Ito M, Nishizawa H, Kato T, Minami Y, Inagaki H, Ohye T, Miyata M, Boda H, Kiriyama Y, Kuroda M, Sekiya T, Kurahashi H, Fujii T	Intragenic duplication in the PHKD1 gene in autosomal recessive polycystic kidney disease.	BMC Med Genet	16(1)	98	2015
Ohye T, Kawamura Y, Inagaki H, Yoshikawa A, Ihira M, Yoshikawa T, Kurahashi H	A simple cytogenetic method to detect chromosomally integrated human herpesvirus-6.	J Virol Methods	228	74-8	2016
Markoff A, Kurahashi H, Grandone E, Bogdanova N	Annexin A5 haplotype M2 is not a risk factor for recurrent miscarriages in Northern Europe, is there sufficient evidence?	Reprod Biomed Online	32(5)	469-73	2016
Yokoi S, Ishihara N, Miya F, Tsutsumi M, Yanagihara I, Fujita N, Yamamoto H, Kato M, Okamoto N, Tsunoda T, Yamasaki M, Kanemura Y, Kosaki K, Kojima S, Saitoh S, Kurahashi H, Natsume J.	TUBA1A mutation can cause a hydranencephaly-like severe form of cortical dysgenesis.	Sci Rep	5	15165	2015
Morine M, Kohmoto T, Masuda K, Inagaki H, Watanabe M, Naruto T, Kurahashi H, Maeda K, Imoto I	A unique TBX5 microdeletion with microinsertion detected in patient with Holt-Oram syndrome.	Am J Med Genet A	167(12)	3192-3196	2015

Nakagawa T, Taniguchi-Ikeda M, Murakami Y, Nakamura S, Motooka D, Emoto T, Satake W, Nishiyama M, Toyoshima D, Morisada N, Takada S, Tairaku S, Okamoto N, Morioka I, <u>Kurahashi H</u>, Toda T, Kinoshita T, Iijima K	A novel PIGN mutation and prenatal diagnosis of inherited glycosylphosphatidylinositol deficiency.	Am J Med Genet A	170(1)	183-188	2016
Nakamura Y, Kikugawa S, Seki S, Takahata M, Iwasaki N, Terai H, Matsubara M, Fujioka F, Inagaki H, Kobayashi T, Kimura T, <u>Kurahashi H</u>, Kato H	PCSK5 mutation in a patient with the VACTERL association.	BMC Res Notes	8	228	2015
Taniguchi-Ikeda M, Takeshima Y, Lee T, Nishiyama M, Awano H, Yagi M, Unzaki A, Nozu K, Nishio H, Matsuo M, <u>Kurahashi H</u>, Toda T, Morioka I, Iijima K.	Next-generation sequencing discloses a nonsense mutation in the dystrophin gene from long preserved dried umbilical cord and low-level somatic mosaicism in the proband mother.	J Hum Genet	61(4)	351-355	2016
Boda H, Uchida H, Takaiso N, Ouchi Y, Fujita N, Kuno A, Hata T, Nagatani A, Funamoto Y, Miyata M, Yoshikawa T, <u>Kurahashi H</u>, Inagaki H	A PDE3A mutation in familial hypertension and brachydactyly syndrome.	J Hum Genet	In press	In press	2016
Tsuge I, Morishita M, Kato T, Tsutsumi M, Inagaki H, Mori Y, Yamawaki K, Inuo C, Ieda K, Ohye T, Hayakawa A, <u>Kurahashi H.</u>	Novel FATP4 mutations responsible for ichthyosis prematurity syndrome in a Japanese patient.	Human Genome Variation	2	15003	2015
Tairaku S, Taniguchi-Ikeda M, Okazaki Y, Noguchi Y, Nakamachi Y, Mori T, Kubokawa I, Hayakawa A, Shibata A, Emoto T, <u>Kurahashi H</u>, Toda T, Kawano S, Yamada H, Morioka I, Iijima K	Prenatal genetic testing for familial severe congenital protein C deficiency.	Human Genome Variation	2	15017	2015
Yagasaki H, Shichino H, Shimizu N, Ohye T, <u>Kurahashi H</u>, Yoshikawa T, Takahashi S.	Nine-year follow-up in a child with chromosomal integration of human herpesvirus 6 transmitted from an unrelated donor through the Japan Marrow Donor Program.	Transpl Infect Dis	17(1)	160-1	2015

Miura H, Kawamura Y, Kudo K, Ihira M, Ohye T, <u>Kurahashi H</u>, Kawashima N, Miyamura K, Yoshida N, Kato K, Takahashi Y, Kojima S, Yoshikawa T	Virological analysis of inherited chromosomally integrated human herpesvirus-6 in three hematopoietic stem cell transplant patients.	Transpl Infect Dis	17(5)	728-31	2015
acharoenmuang R, Komoto S, Guntapong R, Ide T, Haga K, Katayama K, Kato T, Ouchi Y, <u>Kurahashi H</u>, Tsuji T, Sangkitporn S, Taniguchi K	Whole genomic analysis of an unusual human G6P[14] rotavirus strain isolated from a child with diarrhea in Thailand: evidence for bovine-to-human interspecies transmission and reassortment events.	PLoS One	10(9)	e0139381	2015
Komoto S, Tacharoenmuang R, Guntapong R, Ide T, Haga K, Katayama K, Kato T, Ouchi Y, <u>Kurahashi H</u>, Tsuji T, Sangkitporn S, Taniguchi K	Emergence and characterization of unusual DS-1-like G1P[8] rotavirus strains in children with diarrhea in Thailand.	PLoS One	10(11)	e0141739	2015
Watanabe S, Shimizu K, <u>Ohashi H</u>, Kosaki R, Okamoto N, Shimojima K, Yamamoto T, Chinen Y, Mizuno S, Dowa Y, Shiomi N, Toda Y, Tashiro K, Shichijo K, Minatozaki K, Aso S, Minagawa K, Hiraki Y, Shimokawa O, Matsumoto T, Fukuda M, Moriuchi H, Yoshiura K, Kondoh T.	Detailed analysis of 26 cases of 1q partial duplication/triplication syndrome.	Am J Med Genet A	170(4)	908-17	2016
Yaoita M, Niihori T, Mizuno S, Okamoto N, Hayashi S, Watanabe A, Yokozawa M, Suzumura H, Nakahara A, Nakano Y, Hokosaki T, Ohmori A, Sawada H, Migita O, Mima A, Lapunzina P, Santos-Simarro F, García-Miñaúr S, Ogata T, Kawame H, Kurosawa K, <u>Ohashi H</u>, Inoue S, Matsubara Y, Kure S, Aoki Y.	Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.	Hum Genet	135(2)	209-22	2016
Shiohama T, Fujii K, Hino M, Shimizu K, <u>Ohashi H</u>, Kambe M, Nakatani Y, Mitsunaga T, Yoshida H, Ochiai H, Shimojo N.	Coexistence of neuroblastoma and ganglioneuroma in a girl with a hemizygous deletion of chromosome 11q14.1-23.3.	Am J Med Genet A.	170(2)	492-7	2016

Takasawa K, Takishima S, Morioka C, Nishioka M, <u>Ohashi H</u>, Aoki Y, Shimohira M, Kashimada K, Morio T.	Improved growth velocity of a patient with Noonan-like syndrome with loose anagen hair (NS/LAH) without growth hormone deficiency by low-dose growth hormone therapy.	Am J Med Genet A	167A(10)	2425-9	2015
Kaneko M, <u>Ohashi H</u>, Takamura T, Kawame H.	Psychosocial Responses to being Identified as a Balanced Chromosomal Translocation Carrier: a Qualitative Investigation of Parents in Japan.	J Genet Couns	24(6)	922-30	2015
Nagata E, Kano H, Kato F, Yamaguchi R, Nakashima S, Takayama S, Kosaki R, Tonoki H, Mizuno S, Watanabe S, Yoshiura K, Kosho T, Hasegawa T, Kimizuka M, Suzuki A, Shimizu K, <u>Ohashi H</u>, Haga N, Numabe H, Horii E, Nagai T, Yoshihashi H, Nishimura G, Toda T, Takada S, Yokoyama S, Asahara H, Sano S, Fukami M, Ikegawa S, Ogata T.	Japanese founder duplications/triplications involving HLHA9 are associated with split-hand/foot malformation with or without long bone deficiency and Gollop-Wolfgang complex.	Orphanet J Rare Dis	9	125	2015
Nagase H, Ishikawa H, Toyoshima K, Itani Y, Furuya N, <u>Kurosawa K</u>, Hirahara F, Yamanaka M.	Fetal outcome of trisomy 18 diagnosed after 22 weeks of gestation: Experience of 123 cases at a single perinatal center.	Congenit Anom (Kyoto).	Jan;56(1)	35-40	2016
Okamoto N, Toribe Y, Shimojima K, <u>Yamamoto T</u>.	Tatton–Brown–Rahman syndrome due to 2p23 microdeletion.	Am J Med Genet A	In press	In press	2016
Igarashi A, Okumura A, Shimojima K, Abe S, Ikeno M, Shimizu T, <u>Yamamoto T</u>.	Focal seizures and epileptic spasms in a child with Down syndrome from a family with a *PRRT2* mutation.	Brain Dev	In press	In press	2016
Itakura A, Saito Y, Nishimura Y, Okazaki T, Ohno K, Sejima H, <u>Yamamoto T</u>, Maegaki Y.	Successful treatment of migrating partial seizures in Wolf–Hirschhorn syndrome with bromide.	Brain Dev	In press	In press	2016

Sumida K, Inoue K, Takanashi J-I, Sasaki M, Watanabe K, Suzuki M, Kurahashi H, Omata T, Tanaka M, Yokochi K, Iio J, Iyoda K, Kurokawa T, Matsuo M, Sato T, Iwaki A, Osaka H, Kurosawa K, <u>Yamamoto T</u>, Matsumoto N, Maikusa N, Mastuda H, Sato N.	The magnetic resonance imaging spectrum of Pelizaeus–Merzbacher disease: A multicenter study of 19 patients.	Brain Dev	In press	In press	2016
<u>Yamamoto T</u>, Igarashi N, Shimojima K, Sangu N, Sakamoto Y, Shimoji K, Niijima S.	Use of targeted next-generation sequencing for molecular diagnosis of craniosynostosis: identification of a novel de novo mutation of *EFNB1*.	Congenit Anom (Kyoto)	In press	In press	2016
<u>Yamamoto T</u>.	Characteristics of epileptic encephalopathy related to CDLK5 mutations.	J Pediatr Epilepsy	In press	In press	2016
Oka M, Shimojima K, <u>Yamamoto T</u>, Hanaoka Y, Sato S, Yasuhara T, Yoshinaga H, Kobayashi K.	A novel HYLS1 homozygous mutation in living siblings with Joubert syndrome.	Clin Genet	In press	In press	2016
Watanabe S, Shimizu K, Ohashi H, Kosaki R, Okamoto N, Shimojima K, <u>Yamamoto T</u>, Chinen Y, Mizuno S, Dowa Y, Shiomi N, Toda Y, Tashiro K, Shichijo K, Minatozaki K, Aso S, Minagawa K, Hiraki Y, Shimokawa O, Matsumoto T, Fukuda M, Moriuchi H, Yoshiura KI, Kondoh T.	Detailed analysis of 26 cases of 1q partial duplication/triplication syndrome.	Am J Med Genet A	In press	In press	2016
Shimojima K, Okamoto N, <u>Yamamoto T</u>.	A novel *TUBB3* mutation in a sporadic patient with asymmetric cortical dysplasia.	Am J Med Genet A	In press	In press	2016
<u>Yamamoto T</u>, Shimojima K, Yano T, Ueda Y, Takayama R, Ikeda H, Imai K.	Loss-of-function mutations of *STXBP1* in patients with epileptic encephalopathy.	Brain Dev	38	280-4	2016
Ishikawa N, Kobayashi Y, Fujii Y, <u>Yamamoto T</u>, Kobayashi M.	Late-onset epileptic spasms in a patient with 22q13.3 deletion syndrome.	Brain Dev	38	109-12	2016
<u>Yamamoto T</u>, Yoshioka S, Tsurusaki Y, Shino S, Shimojima K, Shigematsu Y, Takeuchi Y, Matsumoto N.	White matter abnormalities in an adult patient with L-2-hydroxyglutaric aciduria.	Brain Dev	38	142-4	2016

Sangu N, Shimojima K, Okumura A, Ando T, Yamamoto T.	Characteristics of patients with benign partial epilepsy in infancy without *PRRT2* mutations.	Epilepsy Res	118	10-13	2015
Shimojima K, Okumura A, Yamamoto T.	A de novo microdeletion involving *PAFAH1B* (*LIS1*) related to lissencephaly phenotype.	Data in Brief	118	488-91	2015
Yamamoto T, Shimojima K, Shibata T, Akiyama M, Oka M, Akiyama T, Yoshinaga H, Kobayashi K.	Novel *PLA2G6* mutations associated with an exonic deletion due to non-allelic homologous recombination in a patient with infantile neuroaxonal dystrophy.	Human Genome Variation	2	15048	2015
Shimojima K, Okumura A, Hayashi M, Kondo T, Inoue H, Yamamoto T.	*CHCHD2* is down-regulated in neuronal cells differentiated from iPS cells derived from patients with lissencephaly.	Genomics	106	196-203	2015
Yamamoto T, Shimada S, Shimojima K, Sangu N, Ninomiya S, Kubota M.	Leukoencephalopathy associated with 11q24 deletion involving the gene encoding hepatic and glial cell adhesion molecule in two patients.	Eur J Med Genet	58	492-6	2015
Yamamoto T, Takanashi J, Kurosawa K, Deguchi K, Osaka H, Inoue K.	Comment on "Delayed myelination is not a constant feature of Allan-Herndon-Dudley syndrome: Report of a new case and review of the literature" by Azzolini S et al. Brain & Development 2014;36:716-720.	Brain Dev	37	988-9	2015
Kawahara T, Watanabe H, Omae R, Yamamoto T, Inazu T.	A novel *PHEX* mutation in Japanese patients with X-linked hypophosphatemic rickets.	Case Rep Genet	2015	301264	2015
Nishigaki S, Hamazaki T, Saito M, Yamamoto T, Seto T, Shintaku H.	Periventricular heterotopia and white matter abnormalities in a girl with mosaic ring chromosome 6.	Mol Cytogenet	8	54	2015
Yamamoto T, Shimojima K, Kimura N, Mogami Y, Usui D, Takayama R, Ikeda H, Imai K.	Recurrent occurrences of *CDKL5* mutations in patients with epileptic encephalopathy.	Human Genome Variation	2	15042	2015
Shimojima K, Okamoto N, Yamamoto T.	Characteristics of 2p15-p16.1 microdeletion syndrome; review and description of two additional patients.	Congenit Anom (Kyoto).	55	125-32	2015

66

Tsurusaki Y, Tanaka R, Shimada S, Shimojima K, Nakashima M, Saitsu H, Miyake N, <u>Yamamoto T</u>, Matsumoto N.	Novel compound heterozygous mutations in *LIAS* cause glycine encephalopathy.	J Hum Genet	60	631-5	2015
Shimada S, Shimojima K, Sangu N, Hoshino A, Hachiya Y, Ohto T, Hashi Y, Nishida K, Mitani M, Kinjo S, Tsurusaki Y, Matsumoto N, Morimoto M, Yamamoto T.	Mutations in the genes encoding eukaryotic translation initiation factor 2B in Japanese patients with vanishing white matter disease.	Brain Dev	37	960-6	2015
<u>Yamamoto T.</u>	Epilepsy in numerical chromosomal abnormalities.	J Pediatr Epilepsy	4	2-3	2015
<u>Yamamoto T</u>, Shimada S, Shimojima K, Ikeda H, Oguni K.	Epilepsy in 1p36 deletion syndrome is not associated with deletion size.	J Pediatr Epilepsy	4	4-7	2015
Okumura A, <u>Yamamoto T</u>, Kurahashi H, Takasu M.	Epilepsies in children with 2q24.3 deletion/duplication.	J Pediatr Epilepsy	4	8-16	2015
Akiyama T, <u>Yamamoto T.</u>	Epilepsy and other symptoms associated with chromosome 9q34.11 microdeletion.	J Pediatr Epilepsy	4	23-9	2015
<u>Yamamoto T</u>, Shimada S, Shimojima K, Eto K, Yoshitomi S, Yanagihara K, Imai K, Oguni H, Okamoto N.	Xq28 duplications and epilepsy: Influence of the combinatory duplication of *MECP2* and *GDI1*.	J Pediatr Epilepsy	4	30-4	2015
Tsurusawa R, Ihara Y, Ogawa A, <u>Yamamoto T.</u>	16p11.2 microdeletion/microduplication syndrome and benign infantile epilepsy.	J Pediatr Epilepsy	4	35-40	2015
Okumura A, Ishii A, Shimojima K, Kurahashi H, Yoshitomi S, Imai K, Imamura M, Seki Y, Shimizu T, Hirose S, <u>Yamamoto T.</u>	Phenotypes of children with 20q13.3 microdeletion affecting *KCNQ2* and *CHRNA4*.	Epileptic Disord	17	165-71	2015
<u>Yamamoto T</u>, Shimojima K.	A novel *MED12* mutation associated with non-specific X-linked intellectual disability.	Human Genome Variation	2	15018	2015
Mimaki M, Shiihara T, Watanabe M, Hirakata K, Sakazume S, Ishiguro A, Shimojima K, <u>Yamamoto T</u>, Oka A, Mizuguchi M.	Holoprosencephaly with cerebellar vermis hypoplasia in 13q deletion syndrome: Critical region for cerebellar dysgenesis within 13q32.2q34.	Brain Dev	37	714-8	2015

Yoshitomi S, Takahashi Y, Ishizuka M, Yamaguchi T, Watanabe A, Nasu H, Ueda Y, Ohtani H, Ikeda H, Imai K, Shigematsu H, Inoue Y, Tanahashi Y, Aiba K, Ohta H, Shimada S, Yamamoto T.	Three patients manifesting early infantile epileptic spasms associated with 2q24.3 microduplications.	Brain Dev	37	874-9	2015
Okumura A, Arai E, Kitamura Y, Abe S, Ikeno M, Fujimaki T, Yamamoto T, Shimizu T.	Epilepsy phenotypes in siblings with Norrie disease.	Brain Dev	37	978-82	2015
Aoyama Y, Yamamoto T, Sakaguchi N, Ishige M, Tanaka T, Ichihara T, Ohara K, Kouzan H, Kinosada Y, Fukao T.	Application of multiplex ligation-dependent probe amplification, and identification of a heterozygous Alu-associated deletion and a uniparental disomy of chromosome 1 in two patients with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency.	Int J Mol Med	35	1554-60	2015
Masuda T, Ueda M, Ueyama H, Shimada S, Ishizaki M, Imamura S, Yamamoto T, Ando Y.	Megalencephalic leukoencephalopathy with subcortical cysts caused by compound heterozygous mutations in *MLC1*, in patients with and without subcortical cysts in the brain.	J Neurol Sci	351	211-3	2015
Shimojima K, Okumura A, Ikeno M, Nishimura A, Saito A, Saitsu H, Matsumoto N, Yamamoto T.	A de novo *TUBB4A* mutation in a patient with hypomyelination mimicking Pelizaeus-Merzbacher disease.	Brain Dev	37	281-5	2015
Shimada S, Shimojima K, Okamoto N, Sangu N, Hirasawa K, Matsuo M, Ikeuchi M, Shimakawa S, Shimizu K, Mizuno S, Kubota M, Adachi M, Saito Y, Tomiwa K, Haginoya K, Numabe H, Kako Y, Hayashi A, Sakamoto H, Hiraki Y, Minami K, Takemoto K, Watanabe K, Miura K, Chiyonobu T, Kumada T, Imai K, Maegaki Y, Nagata S, Kosaki K, Izumi T, Nagai T, Yamamoto T.	Microarray analysis of 50 patients reveals the critical chromosomal regions responsible for 1p36 deletion syndrome-related complications.	Brain Dev	37	515-26	2015

Yamamoto T, Shimojima K, Sangu N, Komoike Y, Ishii A, Abe S, Yamashita S, Imai K, Kubota T, Fukasawa T, Okanishi T, Enoki H, Tanabe T, Saito A, Furukawa T, Shimizu T, Milligan CJ, Petrou S, Heron SE, Dibbens LM, Hirose S, Okumura A.	Single nucleotide variations in *CLCN6* identified in patients with benign partial epilepsies in infancy and/or febrile seizures.	PLoS One	10	e0118946	2015
Shimojima K, Okamoto N, Tamasaki A, Sangu N, Shimada S, Yamamoto T.	An association of 19p13.2 microdeletions with Malan syndrome and Chiari malformation.	Am J Med Genet A	167A	724-30	2015
Chong PF, Haraguchi K, Torio M, Kirino M, Ogata R, Matsukura M, Sakai Y, Ishizaki Y, Yamamoto T, Kira R.	A case of pontine tegmental cap dysplasia with comorbidity of oculoauriculovertebral spectrum.	Brain Dev	37	171-4	2015
Furukawa T, Sakamoto H, Takeuchi S, Ameri M, Kuboki Y, Yamamoto T, Hatori T, Yamamoto M, Sugiyama M, Ohike N, Yamaguchi H, Shimizu M, Shibata N, Shimizu K, Shiratori K.	Whole exome sequencing reveals recurrent mutations in *BRCA2* and *FAT* genes in acinar cell carcinomas of the pancreas.	Sci Rep	5	8829	2015
Okami N1, Aihara Y, Akagawa H, Yamaguchi K, Kawashima A, Yamamoto T, Okada Y.	Network-based gene expression analysis of vascular wall of juvenile Moyamoya disease.	Childs Nerv Syst	31	399-404	2015

IV．研究成果の刊行物・別刷

CrossMark

REVIEW ARTICLE

Preimplantation genetic diagnosis/screening by comprehensive molecular testing

Hiroki Kurahashi[1,2] · Takema Kato[1] · Jun Miyazaki[1,3] · Haruki Nishizawa[3] ·
Eiji Nishio[3] · Hiroshi Furukawa[4] · Hironori Miyamura[3] · Mayuko Ito[3] ·
Toshiaki Endo[5] · Yuya Ouchi[2] · Hidehito Inagaki[1,2] · Takuma Fujii[3]

Abstract Although embryo screening by preimplantation genetic diagnosis (PGD) has become the standard technique for the treatment of recurrent pregnancy loss in couples with a balanced gross chromosomal rearrangement, the implantation and pregnancy rates of PGD using conventional fluorescence in situ hybridization (FISH) remain suboptimal. Comprehensive molecular testing, such as array comparative genomic hybridization and next-generation sequencing, can improve these rates, but amplification bias in the whole genome amplification method remains an obstacle to accurate diagnosis. Recent advances in amplification procedures combined with improvements in the microarray platform and analytical method have overcome the amplification bias, and the data accuracy of the comprehensive PGD method has reached the level of clinical laboratory testing. Currently, comprehensive PGD is also applied to recurrent pregnancy loss due to recurrent fetal aneuploidy or infertility with recurrent implantation failure, known as preimplantation genetic screening. However, there are still numerous problems to be solved, including misdiagnosis due to somatic mosaicism, cell cycle-related background noise, and difficulty in diagnosis of polyploidy. The technology for comprehensive PGD also requires further improvement.

Keywords Microarray · Next-generation sequencing · Preimplantation genetic diagnosis · Recurrent pregnancy loss · Translocation

Introduction

Recurrent pregnancy loss (RPL) is a common clinical condition affecting approximately 5 % of couples trying to conceive [1]. A significant proportion of RPL is associated with chromosomal etiologies. For example, in 3.5 % of couples with RPL, one of the partners is a carrier of a balanced gross chromosomal rearrangement such as translocation or inversion. These particular cases could be treated by preimplantation genetic diagnosis (PGD). PGD involves chromosomal analysis of the fertilized egg using fluorescence in situ hybridization (FISH). Human fertilized eggs undergo cell division about every 24 h, and single blastomere biopsy of the 8-cell stage embryo at day 3 followed by FISH is the conventional approach for PGD. Three-color FISH can theoretically distinguish a cell with balanced chromosomal content from that with an unbalanced chromosome that will result in pregnancy loss.

Nonetheless, the implantation and pregnancy rates of PGD using the conventional FISH method remain suboptimal, partly due to the technical uncertainty of FISH, mostly due to errors caused by overlapping or split signals. Another problem is chromosomal mosaicism among blastomeres, as discussed in detail below. A large series of

✉ Hiroki Kurahashi
kura@fujita-hu.ac.jp

1 Division of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan

2 Genome and Transcriptome Analysis Center, Fujita Health University, Toyoake, Aichi 470-1192, Japan

3 Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan

4 Department of Laboratory Medicine, Fujita Health University Hospital, Toyoake, Aichi 470-1192, Japan

5 Department of Obstetrics and Gynecology, Sapporo Medical University, Sapporo, Hokkaido 060-8543, Japan

Springer

studies show a diagnostic error rate of approximately 10 % [2]. To improve accuracy, FISH using two blastomeres was attempted since it was believed that one or two blastomeres could be taken without damaging the biopsied embryos [3]. However, some studies have indicated that 2-cell biopsy is harmful to the embryo [4]. Another idea is blastocyst biopsy at day 5 to take more trophectodermal cells [5]. However, after the embryo has reached the 8-cell stage, the cells start to compact and the cell size becomes smaller than at the blastomere stage, which might adversely affect the accuracy of the diagnosis [6]. Development of a more secure diagnostic method that can overcome the uncertainty of the conventional FISH method is required.

Comprehensive PGD

Another issue that can affect the pregnancy rate in PGD is the effect of chromosomal aneuploidy. At least 40 % of conceptuses are aneuploid, and most aneuploid conceptuses lead to pregnancy loss [7]. Intrinsically, oocytes undergo errors in chromosome segregation much more frequently than sperm or somatic cells. The origin of the extra chromosome in trisomic fetuses or conceptuses is predominantly maternal [8]. This is because the pachytene checkpoint in the prophase of meiosis I that prevents aneuploidy during gametogenesis is less stringent in oogenesis than spermatogenesis [9, 10]. It also seems likely that the loss of spindle assembly checkpoint occurs during oogenesis when the single egg cell becomes very large [11].

In addition, maternal age considerably affects the rate of chromosomal aneuploidy in conceptuses [8, 12]. The magnitude of the effect is extraordinary: among women under the age of 25 years, ~ 2 % of all pregnancies are trisomic, but, among women over 40 years, this rate increases to 35 %. Age-dependent loss of meiotic cohesion is suggested to be responsible for the age-dependent increase in oocyte aneuploidy [13, 14]. Moreover, translocation affects the segregation error of non-translocated chromosomes via non-homologous synapsis in meiosis, which is called the interchromosomal effect [15]. This proposed mechanism is based on anecdotal observation, but might increase the aneuploidy of the preimplantation embryos, increasing the rate of pregnancy loss. However, the influence of this effect is so low as to be negligible [16].

Thus, in PGD for a couple with a chromosomal translocation carrier, even if the chromosomal content affected by the translocation, balanced or unbalanced, is accurately diagnosed by FISH, the effect of the aneuploidy is too large for the pregnancy rate to be sufficiently improved. To screen more chromosomes, an increased

number of probes has been tried [2]. The application of two or even three rounds of FISH could provide information on 24 chromosomes. However, as far as FISH is concerned, the more probes applied, the greater the chances of diagnostic errors.

Microarray is a useful tool for overcoming these difficulties. The microarray, a tool for comprehensive quantitative analysis of genes, was originally developed for genome-wide expression profiling, in particular, for comparative study between two cell populations. Later, the microarray was used for cytogenetics, and it is now an indispensable tool in molecular cytogenetics to detect submicroscopic deletions and duplications. This technique is a product of a revolutionary idea. In a standard FISH, chromosomes of the samples are placed on a glass slide and labeled probes are hybridized on the slide. In the cytogenetic microarray, numerous probes are placed on the slide, and the genomic DNA of the test samples is labeled and hybridized on the slide. In the earlier studies, two types of platforms were used and compared: microarrays equipped with either oligonucleotide probes or bacterial artificial chromosomes (BAC) clones that have an insert of 200 kb long. The sensitivity of the oligonucleotide microarray was subsequently found to be better [17]. Thus, oligonucleotide microarray is currently the standard technique for the molecular diagnosis of patients with mental retardation or multiple congenital anomalies in clinical settings.

In PGD, only one blastomere or ~ 5 trophectodermal cells can be used for genetic testing. Whole genome amplification (WGA) is required to obtain sufficient genomic DNA for microarray analysis. However, WGA always involves a degree of amplification bias. This bias affects the results of the cytogenetic microarray to varying degrees (Fig. 1). The amplification bias might present as


Fig. 1 Problems associated with WGA in cPGD/PGS. Examples for cPGD are shown. *Upper panel* indicates a standard result for euploid sample, whereas *lower panel* indicates the pseudo-multiple aneuploidy with high background noise produced by the amplification bias or the effect of DNA replication

background noise that is too high to accurately quantify copy numbers or might be falsely interpreted as structural abnormalities [18]. These concerns considerably affect the interpretation of comprehensive PGD (cPGD) results.

Overcoming the amplification bias

Improvements in the cPGD technique have resulted from advances in reducing amplification bias. In earlier studies, cPGD was performed using genomic DNA prepared by a PCR-based amplification method [19]. However, the PCR-based method is always accompanied by an intrinsic amplification bias. Because PCR is based on DNA synthesis, short DNA fragments are preferentially amplified. Another problem is sequence-dependent bias. Amplification of GC-rich regions is difficult because they are more resistant to denaturation and more likely to form secondary structures. Later, a multiple displacement amplification (MDA) method using a phi29 DNA polymerase with strand displacement activity was introduced. Because this polymerase can theoretically resolve secondary structures in template DNA, sequence-dependent WGA bias can be somewhat reduced [20, 21]. However, the bias is still an obstacle for the analysis of a single cell or a small number of cells.

Array comparative genomic hybridization (CGH) is one solution for the amplification bias problem. The sequence-specific amplification bias should be similar among human samples because >99 % of nucleotide sequences are identical. In array CGH, test and reference samples are prepared, labeled with different fluorescent dyes, and simultaneously hybridized to one microarray. When the data are interpreted as a ratio of the two samples, any sequence-specific bias would be offset. Initial CGH analysis was performed on metaphase chromosome specimens, but now on DNA probes spotted or synthesized on the microarray platform [19, 22–24].

Another improvement involves the selection of the microarray probes. The standard oligonucleotide microarray, which shows good performance in clinical pediatrics, is considerably influenced by WGA bias. For WGA-amplified samples, BAC arrays were found to work better because the large size of the probes can dilute the effect of the amplification bias at individual sites [25]. Recently, new WGA technology that can significantly reduce the amplification bias has led to a breakthrough in this field. The method is based on MDA, but the DNA fragments synthesized in the initial amplification cycles form a loop that prevents further amplification, which is called multiple annealing and looping-based amplification cycles (MALBAC) [26, 27]. The combination of this amplification


Fig. 2 Comparison of cPGD by BAC array and NGS. Single cell from EBV-transformed lymphoblastoid cell line with 47,XX,+der(14)t(5;14)(p14.3;p13.2) was subjected to WGA followed by analyses with array CGH using BAC array (**a**) or NGS (**b**). This cell line carries 20.9 Mb partial trisomy at 5p and 13.2 Mb partial trisomy at 14p. In this case, sensitivity appears better in NGS than BAC array

method and the array CGH on the BAC array has yielded good performance in PGD [28]. Currently, the BAC array-based protocol (3000 probes per haploid genome) is becoming the standard technique in cPGD for translocation carriers (Fig. 2a).

On the other hand, in the case of the oligonucleotide microarray, dilution of the effect of the amplification bias could be achieved by altering the setup of the window when the raw data are being analyzed. The processed data obtained by averaging the signal intensities of the probes within the window appear to be reasonably accurate. More recently, an array platform specific for PGD was also designed by the selection of probes that are not subject to an amplification bias [29]. These efforts have improved the quality of the cPGD data from the molecular biology research level to that of the clinical laboratory test.

Problems remaining

One of the problems still affecting the interpretation of the results is mosaicism. Blastomeres in cleavage stage embryos show a high rate of mosaicism for aneuploidy, as well as structural abnormalities [30]. In general, chromosome segregation is strictly regulated by the spindle assembly checkpoint. However, in the oocyte or blastomere, where the protein components are diluted in a large cell volume, the function of the spindle assembly checkpoint is transiently deficient, leading to a high rate of mosaicism in this period [11]. This phenomenon raises a fundamental question of whether data obtained from a single blastomere can represent the data of the embryo. Thus, sampling of 3–5 cells by trophectoderm biopsy is now becoming a mainstream approach in cPGD.

Aneuploidy mosaicism in the blastomere stage leads to another aspect that complicates the interpretation of the PGD results: self-correction. A considerable number of embryos showing aneuploidy in the blastomere biopsy undergo self-correction and become euploid embryos during further culture [31, 32]. This means that a low rate of mosaicism might be insignificant. Experimental data using a mixture of DNA from euploid cells and aneuploid cells show that samples with mosaic rates of more than 25 % can be detected by cytogenetic array [33]. This detection rate might be reasonable for missing the low rate of mosaicism of aneuploids intentionally.

Next, cell cycle-related problems also affect the results. In humans, DNA replication starts at more than 10,000 sites throughout the genome. During S phase, the DNA copy number status is like a patchwork. The genomic regions where the DNA replication has already finished have two copies and the remaining regions still have only one copy. This is also a serious problem because these copy number differences might be falsely interpreted as structural abnormalities or might present as high background noise [34, 35]. To avoid this phenomenon, it might be possible to perform sampling just after the cell division under continuous observation using a live imaging system. If the number of cells for the test sample can be increased by trophectoderm biopsy in the blastocyst stage, the effects of different DNA replication timing in each cell might be reduced.

Further, the detection of polyploidism by cytogenetic microarray is generally difficult. Because triploidy is one of the most frequently observed chromosomal aberrations in the aborted fetus, a failure to detect triploidy might affect the birth rate. Using both 46,XX and 46,XY samples as references, the ratio of sex chromosome signals in the test sample relative to references can give some information regarding the polyploidy, but the results are still ambiguous. Microarrays equipped with probes for genotyping of single nucleotide polymorphisms (SNPs) can be used for the detection of polyploidy, but current SNP arrays are not optimized for WGA [36]. Hopefully, SNP array platforms that can show quantitative signals after WGA will be developed.

Preimplantation screening

As mentioned above, a significant proportion of RPL is associated with chromosomal etiologies. Although one of the partners in 3.5 % of couples with RPL is a carrier of a balanced gross chromosomal rearrangement, some couples have normal karyotypes but undergo RPL due to recurrent fetal aneuploidy. These couples undergo the loss of multiple pregnancies due to trisomy of different chromosomes, called heterotrisomy [37, 38]. Recent studies indicate that greater than 60–90 % of all first trimester miscarriages may be the result of aneuploidy [39]. However, these RPL couples are likely to carry susceptibility for aneuploidy in gametes [40, 41]. Such couples with RPL can be theoretically treated by the screening of 24 chromosomes in PGD, referred to as preimplantation genetic screening (PGS).

A similar situation also arises due to an advanced maternal age [8]. For women above 40 years of age, the miscarriage rate is as high as 45 % [42]. Because most pregnancy losses in this context are due to chromosomal aneuploidy, it is reasonable to imagine that PGS might benefit these couples. In addition, some couples with recurrent implantation failure might be candidates for PGS because a subset of these failures might be due to recurrent chromosomal aneuploidy in their zygotes [43].

Initial PGS attempts involved screening by multicolor and multicycle FISH, but optimal results were not obtained because the number of examined chromosomes was limited

and the resolution of the signal was low [44]. Next, establishment of 24-chromosome screening was achieved by technical improvements in cytogenetic microarrays. PGS is much easier than cPGD because the patients need only the copy number information of the entire chromosome, which is much larger than the unbalanced region of the reciprocal translocations. The European Society of Human Reproduction and Embryology PGD Consortium has reported four times more oocyte retrievals for PGS than for PGD in couples with cytogenetic abnormalities [45]. In Japan, the Japanese Society of Obstetrics and Gynecology will start a 3-year randomized clinical trial to investigate the effectiveness of PGS for couples with RPL or recurrent implantation failure.

However, these patient groups consist of couples with RPL or infertility with heterogeneous etiologies. It is important to identify the couples who can potentially benefit from PGS prior to the procedure. Clinical research combined with genetic analyses should be used to identify susceptibility genes for chromosomal aneuploidy in gametes. Hopefully, personalized medicine for RPL or recurrent implantation failure will one day be established.

Emergence of next-generation sequencing

Since the emergence of next-generation sequencing (NGS), genetic analysis has undergone a dramatic paradigm shift. NGS is a powerful tool that can allow both qualitative and quantitative analyses to be simultaneously performed. Exome analysis is the best example. Previously, patients with possible Mendelian disease were screened by the Sanger sequence for genetic alterations at the nucleotide resolution, whereas multi-exon deletions/duplications were screened by cytogenetic microarray or a different technology, multiplex ligation-dependent probe amplification. In contrast, exome analysis enables genome-wide mutation screening and, at the same time, quantitative analysis of the exome data provides information on multi-exon deletions/ duplications [46]. In this sense, NGS might replace the cytogenetic microarray in the near future.

In these days, NGS is commonly used for chromosomal copy number analysis, particularly in the non-invasive prenatal test for trisomy detection. Fetal DNA can be found in maternal plasma as cell-free fetal DNA, but only as a minor fraction (~ 10 %). Massive parallel sequencing by NGS followed by quantitative determination according to chromosomal assignment enables the prediction of fetal aneuploidy [47, 48].

In cPGD/PGS, the copy numbers of 24 chromosomes are estimated in a similar way [49]. Indeed, WGA-amplified genomic DNA is sequenced using an NGS-based protocol. Approximately three million sequence reads are

mapped and divided into ~ 1 Mb windows (2500 windows per haploid genome), and then reads in each window are quantified. NGS-based cPGD/PGS appears to be more versatile than microarrays (Fig. 2b). In general, only 0.02 times coverage of the whole genome is enough to identify not only the copy number abnormalities of whole chromosomes, but also those derived from unbalanced translocations. If the sensitivity needs to be increased to detect smaller unbalanced regions, sequence reads can be increased accordingly. The size or position of the window can also be modified for specific cases.

Some ethicists and sociologists have ethical concerns about whole genome embryo sequencing. If people know the nucleotide sequences of all of the genes of their offspring, they would want to know not only the genetic information regarding disease susceptibility, but also that of learning ability or athletic performance. Finally, people might want to change the genetic code of the embryos, leading to "designer babies". For cPGD/PGS, sequence information obtained by the current protocol is equivalent to only 0.02 times coverage of the whole genome. However, it is technically easy to obtain the sequence data of the entire genome. In Japan, the Japanese Society of Obstetrics and Gynecology has not yet permitted PGS in clinical practice. Because the permission of an academic society might lower the hurdle, this issue requires careful handling.

Conclusions

By overcoming the WGA bias, cPGD/PGS has recently become the standard technique in the clinical setting. For couples with a balanced translocation, the sensitivity of the detection of small unbalanced translocations needs to be tested. The procedure needs to be optimized on an individual basis and tailor-made protocols are required. Although it still has some problems, including incidental findings, cPGD/PGS is likely to benefit some couples with RPL or infertility. However, it would be better to determine who can benefit by using a blood test for any susceptibility gene before cPGD/PGS. Of course, it is also important to support the right of refusal when it comes to cPGD/PGS.

Compliance with ethical standard

Conflict of interest Hiroki Kurahashi, Takema Kato, Jun Miyazaki, Haruki Nishizawa, Eiji Nishio, Hiroshi Furukawa, Hironori

Miyamura, Mayuko Ito, Toshiaki Endo, Yuya Ouchi, Hidehito Inagaki, and Takuma Fujii declare that they have no conflict of interest.

Human rights statements and informed consent Human rights statements and informed consent: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all patients for being included in the study.

Human/animal studies This article does not contain any studies with human or animal subjects performed by any of the authors.

References

1. Sierra S, Stephenson M. Genetics of recurrent pregnancy loss. Semin Reprod Med. 2006;24(1):17–24 **(review)**.
2. Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. Lancet. 2004;363(9421):1633–41 **(review)**.
3. Van de Velde H, De Vos A, Sermon K, Staessen C, De Rycke M, Van Assche E, Lissens W, Vandervorst M, Van Ranst H, Liebaers I, Van Steirteghem A. Embryo implantation after biopsy of one or two cells from cleavage-stage embryos with a view to preimplantation genetic diagnosis. Prenat Diagn. 2000;20(13):1030–7.
4. Cohen J, Munné S. Two-cell biopsy and PGD pregnancy outcome. Hum Reprod. 2005;20(8):2363–4 **(author reply 2364–5. No abstract available)**.
5. Ruangvutilert P, Delhanty JD, Serhal P, Simopoulou M, Rodeck CH, Harper JC. FISH analysis on day 5 post-insemination of human arrested and blastocyst stage embryos. Prenat Diagn. 2000;20(7):552–60.
6. Sermon K. Current concepts in preimplantation genetic diagnosis (PGD): a molecular biologist's view. Hum Reprod Update. 2002;8(1):11–20.
7. Nagaoka SI, Hassold TJ, Hunt PA. Human aneuploidy: mechanisms and new insights into an age-old problem. Nat Rev Genet. 2012;13(7):493–504. doi:10.1038/nrg3245 **(review)**.
8. Hassold T, Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet. 2001;2(4):280–91 **(review)**.
9. Kurahashi H, Bolor H, Kato T, Kogo H, Tsutsumi M, Inagaki H, Ohye T. Recent advance in our understanding of the molecular nature of chromosomal abnormalities. J Hum Genet. 2009;54(5):253–60. doi:10.1038/jhg.2009.35 **(epub 2009 Apr 17. review)**.
10. Kurahashi H, Kogo H, Tsutsumi M, Inagaki H, Ohye T. Failure of homologous synapsis and sex-specific reproduction problems. Front Genet. 2012;3:112. doi:10.3389/fgene.2012.00112 **(eCollection 2012)**.
11. Shao H, Li R, Ma C, Chen E, Liu XJ. Xenopus oocyte meiosis lacks spindle assembly checkpoint control. J Cell Biol. 2013;201(2):191–200. doi:10.1083/jcb.201211041 **Epub 2013 Apr 8**.
12. Munné S, Chen S, Colls P, Garrisi J, Zheng X, Cekleniak N, Lenzi M, Hughes P, Fischer J, Garrisi M, Tomkin G, Cohen J. Maternal age, morphology, development and chromosome abnormalities in over 6000 cleavage-stage embryos. Reprod Biomed Online. 2007;14(5):628–34.
13. Hodges CA, Revenkova E, Jessberger R, Hassold TJ, Hunt PA. SMC1beta-deficient female mice provide evidence that cohesins are a missing link in age-related nondisjunction. Nat Genet. 2005;37(12):1351–5 **(epub 2005 Oct 30)**.
14. Tsutsumi M, Fujiwara R, Nishizawa H, Ito M, Kogo H, Inagaki H, Ohye T, Kato T, Fujii T, Kurahashi H. Age-related decrease of meiotic cohesins in human oocytes. PLoS ONE. 2014;9(5):e96710. doi:10.1371/journal.pone.0096710 **(eCollection 2014)**.
15. Blanco J, Egozcue J, Vidal F. Interchromosomal effects for chromosome 21 in carriers of structural chromosome reorganizations determined by fluorescence in situ hybridization on sperm nuclei. Hum Genet. 2000;106(5):500–5.
16. Munné S, Escudero T, Fischer J, Chen S, Hill J, Stelling JR, Estop A. Negligible interchromosomal effect in embryos of Robertsonian translocation carriers. Reprod Biomed Online. 2005;10(3):363–9.
17. Ou Z, Kang SH, Shaw CA, Carmack CE, White LD, Patel A, Beaudet AL, Cheung SW, Chinault AC. Bacterial artificial chromosome-emulation oligonucleotide arrays for targeted clinical array-comparative genomic hybridization analyses. Genet Med. 2008;10(4):278–89. doi:10.1097/GIM.0b013e31816b4420.
18. Vanneste E, Voet T, Le Caignec C, Ampe M, Konings P, Melotte C, Debrock S, Amyere M, Vikkula M, Schuit F, Fryns JP, Verbeke G, D'Hooghe T, Moreau Y, Vermeesch JR. Chromosome instability is common in human cleavage-stage embryos. Nat Med. 2009;15(5):577–83. doi:10.1038/nm.1924 **Epub 2009 Apr 26**.
19. Wells D, Sherlock JK, Handyside AH, Delhanty JD. Detailed chromosomal and molecular genetic analysis of single cells by whole genome amplification and comparative genomic hybridisation. Nucleic Acids Res. 1999;27(4):1214–8.
20. Handyside AH, Robinson MD, Simpson RJ, Omar MB, Shaw MA, Grudzinskas JG, Rutherford A. Isothermal whole genome amplification from single and small numbers of cells: a new era for preimplantation genetic diagnosis of inherited disease. Mol Hum Reprod. 2004;10(10):767–72 **Epub 2004 Aug 20**.
21. Hellani A, Coskun S, Benkhalifa M, Tbakhi A, Sakati N, Al-Odaib A, Ozand P. Multiple displacement amplification on single cell and possible PGD applications. Mol Hum Reprod. 2004;10(11):847–52 **Epub 2004 Oct 1**.
22. Hu DG, Webb G, Hussey N. Aneuploidy detection in single cells using DNA array-based comparative genomic hybridization. Mol Hum Reprod. 2004;10(4):283–9 **Epub 2004 Jan 29**.
23. Le Caignec C, Spits C, Sermon K, De Rycke M, Thienpont B, Debrock S, Staessen C, Moreau Y, Fryns JP, Van Steirteghem A, Liebaers I, Vermeesch JR. Single-cell chromosomal imbalances detection by array CGH. Nucleic Acids Res. 2006;34(9):e68.
24. Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K, Carter NP, Speicher MR. High resolution array-CGH analysis of single cells. Nucleic Acids Res. 2007;35(3):e15 **(epub 2006 Dec 18)**.
25. Wells D, Alfarawati S, Fragouli E. Use of comprehensive chromosomal screening for embryo assessment: microarrays and CGH. Mol Hum Reprod. 2008;14(12):703–10. doi:10.1093/molehr/gan062 **Epub 2008 Oct 28**.
26. Zong C, Lu S, Chapman AR, Xie XS. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science. 2012;338(6114):1622–6. doi:10.1126/science.1229164.
27. Hou Y, Fan W, Yan L, Li R, Lian Y, Huang J, Li J, Xu L, Tang F, Xie XS, Qiao J. Genome analyses of single human oocytes. Cell. 2013;155(7):1492–506. doi:10.1016/j.cell.2013.11.040.
28. Fiorentino F, Spizzichino L, Bono S, Biricik A, Kokkali G, Rienzi L, Ubaldi FM, Iammarrone E, Gordon A, Pantos K. PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. Hum Reprod. 2011;26(7):1925–35. doi:10.1093/humrep/der082 **Epub 2011 Apr 12**.
29. Konstantinidis M, Alfarawati S, Hurd D, Paolucci M, Shovelton J, Fragouli E, Wells D. Simultaneous assessment of aneuploidy, polymorphisms, and mitochondrial DNA content in human polar